Back to Awarded Treatment Trials


Awarded Trial: 11T-002

Investigators conducted a 12-week double-blind, randomized study administering adjunctive treatment consisting of salsalate (4g/day), fluvastatin (40mg/day), and omega-3 fatty acids (700 mg/day EPA, 480 mg/day DHA), versus placebo to 39 participants with schizophrenia with persistent positive symptoms. There was no significant benefit of the combined anti-inflammatory treatment versus placebo on global psychopathology, positive, negative, or depressive symptoms, or cognitive impairment.

Grant ID

11T-002

Illness

Schizophrenia

Primary Drug/Intervention

Salsalate

Primary Dosage

4 g/day

Secondary Drug Intervention

flavastatin

Secondary Dosage

40 mg/day

Other Drug/Intervention

omega-3 (EPA and DHA)

Other Dosage

2 g/day

Status

Completed

Investigator

Buchanan

Sample Size

39

Duration of Study Period for Each Subject

8 weeks

Outcome Measurements

N/A

Results

N/A

Publication

N/A

Link

N/A

PI Name

Robert Buchanan

Degree

MD

Center

Maryland Psychiatric Research Center

Institution

N/A

Address

Spring Grove Hospital Grounds, Maple and Locust Streets, PO Box 21247

City or Town

Catonsville

State or Province

MD

Zip or Postal Code

21247

Country

N/A

Email Address

rwbuchanan@mprc.umaryland.edu